In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods

被引:100
作者
Jacqueline, C
Caillon, J
Le Mabecque, V
Miègeville, AF
Donnio, PY
Bugnon, D
Potel, G
机构
[1] UER Med, Lab Antibiol, UPRES, EA 1156, F-44035 Nantes 01, France
[2] Hop Pontchaillou, Bacteriol Lab, Rennes, France
关键词
oxazolidinones; in vitro susceptibility study; drug combination interactions;
D O I
10.1093/jac/dkg160
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activity of the oxazolidinone linezolid was studied alone and in combination with three antibiotics acting on different cellular targets. Oxazolidinones are bacterial protein synthesis inhibitors that act at a very early stage by preventing the formation of the initiation complex. Combinations of linezolid with gentamicin, vancomycin or rifampicin were evaluated against four methicillin-resistant Staphylococcus aureus strains, using killing curves in conjunction with scanning electron microscopy. Time-kill curves were performed over 24 h using an inoculum of 5 x 10(6)-1 x 10(7) cfu/mL. Linezolid was studied at concentrations of 1 x, 4 x and 8 x MIC, with partner drugs at 8 x MIC. Addition of linezolid resulted in a decrease of antibacterial activity for gentamicin and vancomycin, and linezolid was antagonistic to the early bactericidal activity of gentamicin. Linezolid, in combination with rifampicin, showed an additive interaction for susceptible strains and inhibited rifampicin-resistant variants. Linezolid plus rifampicin appeared to be the most active combination against methicillin-resistant S. aureus strains in time-kill experiments.
引用
收藏
页码:857 / 864
页数:8
相关论文
共 31 条
  • [1] In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model
    Allen, GP
    Cha, R
    Rybak, MJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2606 - 2612
  • [2] Amsterdam D., 1996, Antibiotics in laboratory medicine, V6th ed.
  • [3] AMSTERDAM D, 1991, ANTIBIOTICS LAB MED, P53
  • [4] Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes
    Aoki, H
    Ke, LZ
    Poppe, SM
    Poel, TJ
    Weaver, EA
    Gadwood, RC
    Thomas, RC
    Shinabarger, DL
    Ganoza, MC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1080 - 1085
  • [5] STREPTOMYCIN ACCUMULATION IN SUSCEPTIBLE AND RESISTANT STRAINS OF ESCHERICHIA-COLI AND PSEUDOMONAS-AERUGINOSA
    BRYAN, LE
    VANDENELZEN, HM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1976, 9 (06) : 928 - 938
  • [6] CHIANG F, 2002, 42 INT C ANT AG CHEM, P33
  • [7] Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
    Climo, MW
    Patron, RL
    Archer, GL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) : 1747 - 1753
  • [8] DRUGEON HB, 1987, PATHOL BIOL, V35, P495
  • [9] COMPARATIVE EFFICACIES OF CIPROFLOXACIN, PEFLOXACIN, AND VANCOMYCIN IN COMBINATION WITH RIFAMPIN IN A RAT MODEL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS CHRONIC OSTEOMYELITIS
    DWORKIN, R
    MODIN, G
    KUNZ, S
    RICH, R
    ZAK, O
    SANDE, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) : 1014 - 1016
  • [10] Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330